Clinical trial Recruiting at 5 sites Observational

TAMBE device post-marketing safety and effectiveness for thoracoabdominal and pararenal aortic aneurysms

Official title: GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis Post-Marketing Surveillance

Run by W.L.Gore & Associates · NCT07147569 · Data updated 2026-11-12

This tests whether the TAMBE multi-component device (GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis) is safe and works well for people treated for thoracoabdominal or pararenal aortic aneurysms in Japan.

More Thoracoabdominal Aortic Aneurysm trials

Quick facts

Study typeObservational
SexAll
Enrollment100 (estimated)
SponsorW.L.Gore & Associates
Industry-sponsored
Locations5 sites (Minatoku and 4 other locations)
StatusRecruiting
StartedMarch 27, 2026
Main results expectedFebruary 28, 2034
Study endsFebruary 28, 2034
Registry record updatedMay 5, 2026
Trial IDNCT07147569 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults in Japan with thoracoabdominal or pararenal aortic aneurysms who underwent an attempted implant of the AC component at a participating site.

Probably not a fit

Patients who were not offered or did not undergo an attempted AC implant, or whose anatomy or health status make branched endografting inappropriate, are unlikely to receive benefit from this program.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational post-marketing surveillance program following patients in Japan who had an attempt to implant the GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis (Aortic Component, AC) for thoracoabdominal or pararenal abdominal aortic aneurysms. Participating centers collect real-world data on procedural details, device performance, adverse events, reinterventions, and imaging findings during routine follow-up. Data are reported to the sponsor to characterize safety signals and clinical outcomes in typical practice settings. The program aims to inform clinicians and regulators about device performance outside premarket trials.

Why it matters

Potential benefit: If successful, this could confirm that the TAMBE device is a durable endovascular option for complex aortic aneurysms and improve confidence in patient safety and treatment planning.

How similar studies have gone: Branched and fenestrated aortic endografts have shown promising outcomes in prior clinical experience, but specific post-marketing evidence for this TAMBE configuration remains limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients who were attempted to implant the AC
* Thoracoabdominal aortic aneurysm
* Pararenal abdominal aortic aneurysm

Exclusion Criteria:

* N/A

Where it's running

  • The Jikei University Hospital
    Minatoku, Japan
    Recruiting
  • Nagoya University Hospital
    Nagoya, Japan
    Recruiting
  • Morinomiya Hospital
    Osaka, Japan
    Recruiting
  • Osaka International Medical & Science Center Osaka Police Hospital
    Osaka, Japan
    Recruiting
  • The University of Osaka Hospital
    Suita, Japan
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.